Navigation Links
PrimeraDx Appoints David Jackson as VP of Business Development
Date:1/3/2012

MANSFIELD, Mass., Jan. 3, 2012 /PRNewswire/ -- PrimeraDx today announced that David Jackson has been appointed as the Vice President of Business Development.

"David has extensive capabilities in companion diagnostic partnerships, and his experience with DxS and Qiagen is well aligned with the company's strategy to be the platform of choice in the burgeoning companion diagnostics market," said Matt McManus, President and CEO, PrimeraDx.

"PrimeraDx has the most innovative qPCR based MDx platform in this space," commented Dr. Jackson.  "The strong growth in complex, molecular-based companion diagnostic assays makes this an exciting time to develop strategic alliances based around the high multiplex and multi-modal capabilities of the ICEPlex platform."

David Jackson has over 13 years' experience in the healthcare technology and investment industries.  Most recently David was employed at Qiagen as a member of the Companion Diagnostics Partnerships team in Global Business Development. Prior to Qiagen he held a similar VP role with DxS, which was acquired by Qiagen in 2009.  He has held leadership positions in business and corporate development; strategic marketing; commercialization; and intellectual property analysis. Dr. Jackson earned a doctorate in the medical sciences from the Boston University School of Medicine; is trained and experienced as a US Patent Agent and Securities Analyst.

About PrimeraDx

PrimeraDx is a molecular diagnostics company that has developed, and is commercializing, a novel, game-changing clinical platform which combines PCR with capillary electrophoresis.  The result of combining these two well-known technologies into a bench-top instrument is the ability to deliver highly multiplexed and quantitative, answers to the clinic.  The company is pursuing a two-pronged strategy to sell the system in an Open Platform Mode to clinical labs and to collaborate with pharmaceutical companies to develop high-value companion and enabling diagnostic products.  Users can easily design very complex multi-modal assays that test for disparate target types, like SNPs, expression biomarkers, microRNAs and fusion genes.  PrimeraDx's technology represents the next generation of quantitative PCR.  The Company is backed by a strong group of experienced venture-capital investors, including Abingworth, InterWest Partners, CHL Medical Partners, and Malaysia Technology Development Corporation.  The Company's website is: www.primeradx.com or www.multiplexpcr.com.

CONTACT: Andrew Bond, +1-508-618-2752, abond@primeradx.com


'/>"/>
SOURCE PrimeraDx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PrimeraDx Appoints Leroy Hood to its Scientific Advisory Board
2. PrimeraDx Appoints David Heffelfinger as VP of Engineering and Systems Development
3. PrimeraDx Launches the Only System Capable of Simultaneous Quantification of mRNA, microRNA and DNA
4. China Health Resource Appoints USA Acquisition Counsel
5. Winner Medical Appoints BDO China as Independent Auditor
6. Marken Appoints New Head of Global Quality Assurance
7. Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board
8. Qforma Appoints Ian McGuinness as Vice President, Business Development
9. ZONARE Medical Systems Appoints Timothy S. Heher as Vice President of Finance
10. NeoStem Appoints a Biopharmaceutical Business Leader and a Cellular Therapy Expert to its Board of Directors
11. HealthpointCapital Acquires Blue Belt Technologies, Inc. and Appoints Eric B. Timko as President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... 20, 2017 Avillion LLP, a co-developer and ... Mark Weinberg , MD MBA as Chief Medical Officer. Dr Weinberg ... USA . ... Dr Weinberg has spent more than 17 years as a pharmaceutical ... to micro-cap biotech. Over the course of his career, he has ...
(Date:1/19/2017)... -- Report Details What can be expected ... to grow at the fastest rates? This visiongain report ... opportunities and prospects. Our 190-page report provides 124 ... in the industry and the future market prospects. Our ... all the major categories of the ophthalmic devices market. ...
(Date:1/19/2017)... -- Conference Call and Webcast to Follow Vanda Pharmaceuticals ... release results for the fourth quarter of 2016 on Wednesday, February ... ... 4:30 PM ET on Wednesday, February 15, 2017, during which management ... and other corporate activities. To participate in the conference call, please ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... ... Christmas:” a beautiful and enchanting tale that teaches children the true meaning of Christmas. “Journey ... Oklahoma City, and a devoted woman of faith. , “Becoming a parent changes you. ... of my mind for years, but actually doing it might have been a while in ...
(Date:1/19/2017)... ... ... the Centers for Medicare & Medicaid Services (CMS) announced over 359,000 clinicians are ... who participate in APMs are paid for the quality of care they give to ... a system that delivers better care and one in which clinicians work together to ...
(Date:1/19/2017)... ... 2017 , ... With the cold weather here, many people will have to clear snow with ... large amounts of snow, but they can be dangerous when used incorrectly. That’s why ... for the proper use of snow blowers:, , When removing wet ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... solutions, has recently unveiled impressive transportable capabilities with their iMedHD2™ Portable Teleultrasound ... an extension to RMT technology that delivers HD, dynamic, streaming ultrasound images and ...
(Date:1/19/2017)... NJ (PRWEB) , ... January 19, 2017 , ... ... certified dermatologist by the American Board of Dermatology and fellowship trained Mohs and ... the National Institutes of Health, Dr. Li completed his internship in internal medicine ...
Breaking Medicine News(10 mins):